I casually searched on Baidu for your reference: 1. The Medicinal Value of Yew Trees. In Chinese medicine, the yew tree has been recorded since ancient times: *Compendium of Materia Medica* records its efficacy in treating cholera, typhoid fever, and detoxification; in ancient pharmacological books such as *Great Dictionary of Chinese Medicine*, *Northeastern Pharmacopoeia*, *Jilin Herbal Medicine*, and *Promoting the Compendium of Materia Medica*, there are further records. The leaves of the yew tree contain taxine diterpenoid compounds, taxol A, taxol H, taxol K, taxol L, golden pine flavone, ponasterone A, ecdysterone, golden pine double flavone, volatile oil, sugar, etc.; the stem bark contains taxifolin, which has anti-leukemia and anti-tumor effects; branches contain taxine, heartwood contains taxol, taxine has a hypoglycemic effect on hyperglycemia (adrenaline or food-induced). Leaves and branches used in medicine have the effects of promoting menstruation, diuresis, controlling diabetes, and treating heart disease. Internationally, paclitaxel extracted from the bark and tender leaves of the yew tree is recognized as the best broad-spectrum, highly active natural anticancer drug after hemycin and cisplatin. Paclitaxel was first isolated by Wani et al. from the bark of short-leaf yew (*Taxus brevifolia*) in the United States and officially launched in the U.S. market in January 1993. According to clinical trial results compiled by the U.S. National Cancer Institute (NCI), paclitaxel shows significant efficacy against various cancers, with an overall effectiveness rate exceeding 75%. It is mainly used to treat advanced breast cancer, lung cancer, ovarian cancer, head and neck cancer, soft tissue cancer, and gastrointestinal cancer. Paclitaxel inhibits the formation of spindles and spindle fibers in late-stage cancer, thereby inhibiting mitosis and preventing the proliferation of cancer cells. Yew branches and leaves are used to treat leukemia, nephritis, diabetes, and polycystic kidney disease. Paclitaxel has subsequently been approved as an anticancer drug in more than 40 countries including the United States, the United Kingdom, France, Japan, Italy, Canada, Sweden, Germany, and China, sparking a global craze for yew-derived paclitaxel. With the annual increase in global demand for paclitaxel and enormous commercial profits (over $1,000 per gram), excessive logging of yew trees has occurred. However, the content of paclitaxel in wild yew resources is extremely low, only 0.006% to 0.06% of dry weight. Additionally, yew species are naturally scattered without pure forests, characterized by "mixed growth, multiple layers, and varied ages," along with slow growth and difficulty in natural regeneration, making resources easily damaged. China's wild yew resources have also suffered severe damage and are now strictly controlled for logging. Therefore, research on clinical applications of paclitaxel and rational development and utilization of this genus of plants have become hotspots both domestically and internationally. 2. Ornamental Value of Yew Trees. The yew tree has a graceful posture, with a purple-red straight trunk, and seeds that turn red when mature, with bright arils. Simultaneously, the various alkaloid gases it secretes purify the air and have health-care benefits, making it an excellent ornamental tree species in gardens. The wood of the yew tree is tough, with fine straight grain and a light red color, offering unique value for potted plant appreciation. Northeast yew bonsai treated with dwarfing technology has an ancient and elegant shape, with compact but not dense branches and leaves, spreading yet not loose, red stems, red branches, green leaves, and red seeds, providing multiple appreciative values of stem, branch, leaf, and fruit observation. The yew tree is a species with extremely high economic value, integrating medicinal use, ornamental value, and cancer prevention and health care, regarded as a "national treasure" worldwide. 3. Research and Development of Yew Trees. As early as 1856, Lucas extracted powdered alkaline components called tannins from the leaves of yew (*Taxus baeeata L.*). However, it wasn't until the 1960s, with the rapid development of spectroscopy technology, that more in-depth studies were conducted. During this period, Japan and the United States respectively isolated over 20 new taxane diterpenoid compounds from Northeast yew and berry yew. In 1971, American chemist Wani et al. separated a highly active anticancer taxane diterpenoid compound, paclitaxel, from the bark of short-leaf yew (*Taxus brevifolia*) found in North America. They discovered that paclitaxel had unique antitumor properties, binding to tubulin proteins to form stable microtubules and causing depolymerization, halting cancer cells in the late G2 phase or M phase, inhibiting cell replication, and preventing the proliferation of cancer cells. This unique function attracted significant attention from NCI, promoting clinical trial research. Clinical research on paclitaxel began in 1982, completing Phase I and II clinical trials by 1989, and Phase III clinical trials in 1990. On December 29, 1992, the U.S. Food and Drug Administration (FDA) officially approved its use as an anticancer drug for advanced ovarian cancer, lung cancer, uterine cancer, etc. The drug was approved within just five months from application, setting a record for the shortest approval time for a new drug in the United States. The launch of paclitaxel immediately made it one of the hottest anticancer drugs globally, and currently, more than 40 countries worldwide use paclitaxel. Currently, the main products produced domestically include Taxol, Taxotere, Docetaxel, Compound Taxus Capsules, etc., in injectable and capsule forms, produced in places like the Chinese Academy of Medical Sciences, Shanghai Medical College, Heilongjiang Province, Liaoning Province, and others. China also organized experts in the late 1980s to conduct in-depth research on paclitaxel and yew components. On September 20, 1996, Professor Yan Jiaqi at the Strategy Research Conference on New Chinese Herbal Drugs published three consecutive papers on the pharmacological research of yew and the clinical inhibition of tumors and cancer cells by paclitaxel. Due to the extremely low paclitaxel content in wild yew trees, it has limited the development of paclitaxel pharmaceuticals, thus making the research to break through the limitation of paclitaxel content a priority. To address the issue of paclitaxel drug sources, people have started research in the following areas: (1) Chemical Synthesis Pathway: Reports indicate that extracting 10-deacetylbaccatin III from yew needles and synthesizing paclitaxel through four-step reactions has made significant progress, but it still lacks practical application value. (2) Microbial Production: Stierle et al. isolated a parasitic fungus (*Taxomyces andreanae*) from the phloem of short-leaf yew, which can produce paclitaxel under specific culture conditions, but due to extremely low yield (24~50 ng/L), improving cultivation conditions and using recombinant DNA technology may enhance paclitaxel production. (3) Biotechnological Route: Research on in vitro culture of yew trees began in the early 1950s. In 1991, Phyton Catalytic Company in the United States applied for and obtained the first patent related to producing paclitaxel via tissue culture. To date, over 20 patents have been applied for and approved, covering almost all aspects of bioengineering research on yew tissue and cell cultures. By adding precursors and inducers, improving medium composition and cultivation methods, the paclitaxel content in cells has been increased to varying degrees, and some large-scale cultivation experiments have been conducted. Cells screened by Cornell University can produce 1~20 mg/L paclitaxel, but there are no reports of commercial-scale production yet. To resolve the increasingly acute problem of raw material scarcity, although domestic and international efforts through chemical synthesis, genetic engineering, fungal fermentation, and cell culture have alleviated the issue somewhat, protecting existing resources, studying seedling cultivation techniques, selecting superior clones, and conducting yew tissue culture research remain the only fundamental solutions to the paucity of paclitaxel raw materials. Typically, the paclitaxel extraction yield from yew trees is less than 0.01%~0.03%, meaning that producing one kilogram of paclitaxel requires over 30,000 kilograms of yew branches! But currently, with this resource shortage, to expand the development of this industry, the direct method is to increase the capacity for seedling propagation and expand the planting area of yew forests. Although, in 1996, new varieties like "Mandian Yew" were introduced from Europe and America, whose paclitaxel content has been proven to reach 0.04%~0.08% or more, this is undoubtedly an effective way to improve efficiency, but due to their introduction in 1996, slower growth rates, and fewer species numbers, they are still insufficient to solve this prominent issue. Therefore, how to quickly propagate and produce these new varieties with higher paclitaxel content—Mandian Yew—has become an urgent matter! Osmanthus is not uncommon. Having paid homage to many famous mountains and scenic waters around the world, one can almost always see its charming silhouette. However, the vast majority are pale yellow. The most famous is probably the Osmanthus Street in Guilin, where during the Mid-Autumn Festival, crowds gather to admire the osmanthus flowers, which are white with a hint of yellow, “faintly light yellow and gentle in nature.” Beautiful as they are, upon closer inspection, they seem somewhat delicate. The osmanthus flowers in Hangzhou, elegant, pure, and unrestrained, are also yellow. Their ethereal beauty has inspired countless poetic verses. Bai Letian sang, “Searching for osmanthus seeds in the mountain temple under the moonlight, watching the tidal waves from the city pavilion.” It truly feels otherworldly. In contrast, the Dan Gui in Pucheng gives a distinctly different impression.